Document is current
Any future updates will be listed below
-
Authors
Palmer, Douglas
Webber, Beau
Patel, Yogin
Johnson, Matthew
Kariya, Christine
Lahr, Walker
Parkhurst, Maria
Gartner, Jared
Prickett, Todd
Lowery, Frank
Kishton, Rigel
Gurusamy, Devikala
Franco, Zulmarie
Vodnala, Suman
Diers, Miechaleen
Wolf, Natalie
Slipek, Nicholas
McKenna, David
Sumstad, Darin
Viney, Lydia
Henley, Tom
Bürckstümmer, Tilmann
Baker, Oliver
Hu, Ying
Yan, Chunhua
Meerzaman, Daoud
Padhan, Kartik
Lo, Winnie
Malekzadeh, Parisa
Jia, Li
Deniger, Drew
Patel, Shashank
Robbins, Paul
Scott McIvor, R
Choudhry, Modassir
Rosenberg, Steven
Moriarity, Branden
Restifo, Nicholas
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04426669 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
https://doi.org/10.1136/jitc-2023-006822
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
https://doi.org/10.1136/jitc-2021-004244
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program
https://doi.org/10.1136/jitc-2020-sitc2020.0333
- License Information
